Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 2Gastrointestinal 2CNS 2Tumor-Agnostic 1Myeloid 1Gynecologic 1

Conditions

Brain Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 66Radiotherapy 52Carboplatin 25Bevacizumab 21Cisplatin 19Radiosurgery 18Vincristine 17Etoposide 17Cyclophosphamide 17Surgical Procedures, Operative 13Magnetic Resonance Spectroscopy 13Chemotherapy, Adjuvant 11Melphalan 10Lomustine 10Drug Therapy 10Filgrastim 9Erlotinib Hydrochloride 9apatinib 8Pemetrexed 83-Iodobenzylguanidine 8anlotinib 7Radiation 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Thiotepa 6Isotretinoin 6Irinotecan 6Ifosfamide 6Doxorubicin 6Carmustine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Tyrosine Kinase Inhibitors × CNS × Clear all
NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

NCT03424980 2018-02-08

A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors

Tang-Du Hospital

Unknown
200 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡